Clinical Trial

Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2023-10-25; most recent amendment 2025-11-07.
Status change: Recruiting → Active, Not Recruiting 2025-11-07
Status change: Not Yet Recruiting → Recruiting 2024-03-08
Trial Details
NCT Number NCT06109181
Lead Sponsor Lexeo Therapeutics
Conditions Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Enrollment 10 participants
Start Date 2024-02-29
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-11-12